Mail

Australia markets closed

ALL ORDS
7,817.40
-81.50(-1.03%)
ASX 200
7,567.30
-74.80(-0.98%)
AUD/USD
0.6421
-0.0004(-0.07%)
OIL
83.24
+0.51(+0.62%)
GOLD
2,406.70
+8.70(+0.36%)
Bitcoin AUD
100,403.02
+1,335.53(+1.35%)

Bristol-Myers Squibb Company (0R1F.L)

LSE - LSE Delayed price. Currency in USD

Add to watchlist

72.70

+0.20

(+0.28%)

At close: 07:03PM BST

Previous close	72.50
Open	73.28
Bid	0.00 x 0
Ask	0.00 x 0
Day's range	72.71 - 72.83
52-week range	57.97 - 81.40
Volume	470
Avg. volume	354,443

Market cap	1.2B
Beta (5Y monthly)	0.39
PE ratio (TTM)	0.26
EPS (TTM)	N/A
Earnings date	N/A
Forward dividend & yield	N/A (N/A)
Ex-dividend date	N/A
1y target est	N/A

Press releases

Business Wire
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J., April 08, 2024--KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with.....
Business Wire
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
PRINCETON, N.J., April 06, 2024--Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT....
Business Wire
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
PRINCETON, N.J., April 06, 2024--BMS Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia...